SlideShare a Scribd company logo
AKHIL JOSEPH
REG.NO : 13Q0402
DEFINITION
 Tuberculosis is a chronic granulomatous disease
caused by Mycobacterium tuberculosis,which can
produce either a silent ,latent infection or a
progressive,active disease.
ETIOLOGY
 Causative Organism:TB is caused by Mycobacterium
species.
 In humans,infection by M.tuberculosis.
 In animals,infection by M.bovis.
 In Africans,infection by M.africanum
 M.tuberculosis is an aerobic,non-spore forming
bacillus that resist decolourization by acid alcohol
after staining with basic fuschin....organism is referred
to as an acid fast bacilli(AFB).
PATHOPHYSIOLOGY
 Airborne/droplet ingestion (cough, sneezing,speaking)
Droplet nuclei enter the respiratory tract and reach alveoli(bacteria enter
ciliary epithelium)
Initiation of primary infection(organisms multiply)
Activation of alveolar macrophages(phagocytosis of bacilli)
Persistence of organism(few in number)
Rupture of macrophages & release of bacilli
Organisms multiply, transport of bacilli by lymphatic system to other organs
Formation of gra nuloma(cell mediated immunity delayed type of
hypersensitivity by activation of CD4+T cells,secretion of INF gamma, IL )
Large number of macrophages surrounds the organism
In high immune people
disease may relapse after 2
yrs(latent tb infection)
In immune suppressed people tubercular
bacilli appear(rapid multiplication)
Active tb infection
CLINICAL PRESENTATION
SIGNS AND SYMPTOMS:
 Weight loss,fatigue,a productive cough,fever,and night sweats.
 Frank hemoptysis
PHYSICAL EXAMINATION:
 Dullness to chest percussion,rales and increased vocal fremitus are
observed frequently on auscultation.
LAB TESTS:
 Moderate elevations in WBC Count with a lymphocyte predominance.
 Chest Radiograph:Patchy or nodular infiltrates in the apical areas of
the upper lobes or the superior segment of the lower lobes
 Cavitation that may show air fluid levels as the infection progresses.
Definition
AIDS, the acquired immune deficiency syndrome(some
times called as slim disease) is a fatal illness caused by a
retrovirus known as the human immunodeficiency
virus(HIV) which breaks the body’s immune system, leaving
the victim vulnerable to a host of life-threatening
opportunistic infections, neurological disorders, or unusual
malignancies.
ETIOLOGY
 AIDS is caused by HIV, a human retrovirus.
 Two types- HIV I and HIV II which are genetically
different but has related forms.
 HIV I is most common type associated with AIDS in US,
Europe and Central Africa.
 HIV II causes similar disease in West Africa and India.
 HIV-2 is transmitted less efficiently than HIV-1.
0
PATHOPHYSIOLOGY
COMMON SIGN & SYMPTOMS
 Severe impairment or suppression of immune system.
 Pneumocystis carinii pneumonia (pcp) is mostly seen.
 Opportunistic infection
 CD4+T- cells count falls below 200 cells/mm3 of
blood.
 In healthy adult it’s value is 600-1500 cells/mm3 of
blood.
• Weight loss
• Pharyngitis
• Neurological symptoms.
• Rash
• Headache
 Fever
 Lymphadenopathy
DEMOGRAPHIC DETAILS
 PATIENT NAME:ABC
 SEX:M
 DEPT:MEDICINE
 DOA:10-12-2016
 AGE:30yrs
 IP NO:27687
 UNIT:C
 DOD:17-12-2016
REASON FOR ADMISSION
 C/O fever with chills since 1 week.
 C/O cough since 1 week.
 generalisedweakness +
PAST MEDICAL HISTORY
 Not a k/c/o HTN,DM,TB,epilepsy,anaemia
HISTORY OF PRESENT ILLNESS
 Patient was apparently alright but 7 days back he
developed fever with chills,insidious in
onset,intermittent type.
 No H/O rigors
 H/O dry cough since 7 days.
 H/O breathlessness since 7 days.
 H/O generalised weakness +
FAMILY HISTORY
 DIET:mixed
 APPETITE:decreased
 SLEEP:normal
 B/B:regular
SOCIAL HISTORY
 Chronic Alcoholic
 Tobacco Chewing
GENERAL PHYSICAL EXAMINATION
 Patient is moderately built and
nourished,conscious,cooperative,well oriented to
time,place and person.
 O/E,
 PR:90 bpm
 BP:110/70mmHg
 Febrile
1. PICKLE
B/L Pitting pedal edema
SYSTEMIC EXAMINATION
 CVS:S1 S2 +
 RS:NVBS+
 CNS:NAD
 P/A:soft,non-tender,no organomegaly
INVESTIGATIONS
 CBC with ESR
 RBS
 Serum Creatinine
 LFT
 Chest X-Ray
 RVD
 HBsAg
 ECG
 Urine Routine
 Culture sensitivity test
 USG Abdomen
 MP Antigen
PROVISIONAL DIAGNOSIS
CHRONIC ALCOHOLIC CIRRHOSIS OF LIVER ,
SEVERE ANAEMIA ?
LABORATORY DATA
11/12 13/12
Hb 3.3gm/dl(13.5-17.5) 6.0gm/dl
WBC 1500cells/µl(4500-10500) 1800cells/µl
POLYMORPHS 65%(40 -75) 53%
BASOPHILS 00(0-1) 00
EOSINOPHILS 3%(0-5) 2%
LYMPHOCYTES 32%(20-40) 45%
MONOCYTES 00%(0-7) 0%
RBC O.75mill/µ l(4.7-6.1) 1.53mill/µl
PLATELETS 60,000cells/µl(1.5-4.5
lakhs)
110000cells/µl
ESR 100mm at the end of the
1st hour
11/12
RBS 112 mg/dl(60-140)
Sr . Urea 18 mg%(10-50)
Sr . Creatinine 0.9 mg/dl(0.6-1.2)
ALT 22 U/L(6-38)
AST 68 U/L(6-40)
ALP 122 U/L(35-140)
T . Bilirubin 0.8 MG%(0.2-1)
D . Bilirubin 0.3 MG %(0.1-0.4)
I . Bilirubin 0.5 MG %(0.1-0.6)
HIV - 1 Reactive
HBs Ag - ve
Albumin 3.1 gm %(3.5-5.2)
 SPUTUM CULTURE SENSITIVITY TEST : organisms
isolated .
 ZN stain : AFB seen
 USG abdomen : moderate to gross ascitis.
 Pus cells : 1-2/hpf
 Epithelial cells : 0-1/hpf
TREATMENT CHART
BRAND
NAME
GENERIC NAME DOSE ROUTE FREQUENCY 1 2 3 4 5 6 7 8
Blood
Transfusion
PRBC
PACKAGED CELL
VOLUME
3 PINT IV
√ √
INJ.Taxim Cefotaxime 1gm iv 1-0-1 √ √ √ √ √ √
INJ.Pantakind Pantoprazole 40mg iv 1-0-0 √ √ √ √ √ √(
t)
√ √
INJ.Vitcofol
2 ml in 100ml
NS
folic
acid,vitaminB12,nic
otinamide
15mg,
0.15mg,200m
g
im 1-0-0 √ √ √ √ √ √ √ √
IVF DNS 2 pint iv 1-1-1 √ √ √
TAB.Sepmax
DS
Sulphamethoxazole
,trimethoprim
800mg,160m
g
p/o 1-0-0 √ √ √ √ √ √
TAB.Benadon Vit B6 40mg p/o 0-1/2-0 √ √ √ √ √ √
TAB.Akurit 4 INH,rif,pyr,ethamb
utol
75mg,150mg,
400mg,275m
g
p/o 3-0-0 √ √ √ √ √ √
FOLLOW UP
 DAY 1
 O/E,
 BP:100/70 mmHg
 PR:90 bpm
 Febrile
 S/E,
 CVS:S1 S2 +
 RS:NVBS+
 CNS:NAD
 P/A:Soft,non-tender
 Adv:
 Blood transfusion 3 pint whole blood
 Inj.Taxim 1gm iv 1-0-1
 Inj.Pantakind 40 mg iv 1-0-1
 Inj.Vitcofol 2amp in 100 ml NS iv 1-0-0
 IVF DNS 2 pint with mvi
 DAY 2
 O/E,
 BP:110/70mmHg
 PR:80 bpm
 S/E,
 CVS:S1 S2 +
 RS:NVBS+
 CNS:NAD
 P/A:Soft non-tender
 Adv:
 Inj.Taxim 1gm iv 1-0-1
 Inj.Pantakind 40mg iv 1-0-0
 Inj.Vitcofol 2 amp in 100 ml NS iv 1-0 -0
 IVF DNS 2 pint with mvi
 Tab.Sepmax DS 1-0-0
 Tab.Akurit 4 3-0-0
 Tab.Benadon 40mg 0-1/2-0
 DAY 3
 O/E,
 BP:110/60mmHg
 PR:80 bpm
 S/E,
 CVS:S1 S2 +
 RS :NVBS +
 CNS:NAD
 P/A :soft non tender
 Adv:
 Inj. Taxim 1g iv 1-0-1
 Inj. Pantakind 40mg iv 1-0-0
 Inj. Vitcofol 2 amp. In 100 ml NS IV 1-0-0
 Tab.Sepmax DS 1-0-0
 Tab. Akurit 4 3-0-0
 Tab. Benadon 40mg 0-1/2-0
 DAY 4
 O/E,
 BP:120/60mmHg
 PR:88bpm
 Afebrile
 S/E
 CVS:S1,S2 +
 RS:NVBS+
 CNS:NAD
 P/A:Soft non tender
 Adv:
 APC
 DAY 5
 O/E
 BP:110/60mmHg
 PR:88bpm
 Afebrile,
 S/E
 CVS:S1,S2 +
 RS:NVBS+
 CNS:NAD
 P/A:Soft non tender
 Adv:
 APC
 DAY 6
 O/E:
 BP:110/60mmHg
 PR:80bpm
 Afebrile
 S/E:
 CVS:S1,S2 +
 RS:NVBS+
 CNS:NAD
 P/A:Soft non tender
 Adv:
 Tab.pantakind 40 mg 1-0-0
 Inj. Vitcofol 2cc in 100ml NS iv 1-0-0
 Tab.Sepmax DS 1-0-0
 Tab. Akurit 4 3-0-0
 Tab.Benadon 40mg 0-1/2-0
 DAY 7
 O/E:
 BP:110/70mmHg
 PR:84bpm
 S/E:
 CVS:S1,S2 +
 RS:NVBS+
 CNS:NAD
 P/A : Soft non tender
 Adv:
 APC
FINAL DIAGNOSIS
 FROM THE SUBJECTIVE AND OBJECTIVE
EVIDENCES , THE PHYSICIAN DIAGNOSED IT AS
“RVD POSITIVE ,PULMONARY TB ,
PANCYTOPENIA”
DISCHARGE MEDICATION
BRAND GENERIC NAME DOSE ROUTE FREQUENC
Y
DURATION
T.AKURIT 4 INH,PYR,EHAMBUTOL,RIFAM
PICIN
75mg,400mg,2
75mg,150mg
P/O 3-0-0 90 DAYS
T.BENADONE VIT B6 40 mg P/O 0-1/2-0 90 DAYS
T.SEPMAX DS SULPHAMETHOXAZOLE,TRIM
ETHOPRIM
800 mg,160 mg P/O 1-0-0 30DAYS
T.PANTAKIND PANTAPRAZOLE 40 mg P/O 1-0-0 10DAYS
SYP.VICTOFOL FOLIC ACID,VIT
B12,NICOTINAMIDE
15mg,0.15mg,2
00mg
p/o 1-0-0 10DAYS
PHARMACEUTICAL CARE PLAN
 SUBJECTIVE EVIDENCE : c/o fever with chills since 1 week , c/o
cough since 1 week . Generalized weakness +ve
 OBJECTIVE EVIDENCE :
HB : 6gm/dl ↓
WBC : 1500cells/ul ↓
RBC : 1.53mill/ul ↓
PLATELETS : 110000 cells/ul ↓
ESR : 100 mm at the end of the first hour ↑
HIV 1 : REACTIVE
CULTURE SENSITIVITY TEST : Organisms isolated
ZN stain : AFB seen
USG abdomen : moderate gross ascites
ALBUMIN : 3.1 gm%
ASSESSMENT : By observing the subjective and objective
evidences , the physician diagnosed it as “ RVD +ve , PTB ,
PANCYTOPENIA “
PLANNING:
 GOALS OF THE THERAPY :
1. To decrease the fever , chills and cough .
2. To improve patient’s quality of life .
3. To make patient adhere to the medication .
4. To incease Hb and RBC counts .
5. To prevent further oppurtunistic infections.
6. To recommend the best ART regimen.
 GOALS ACHIEVED
1. Fever, chills and cough reduced
2. patients quality of life is improved
3. Haemoglobin and RBC count is increased.
4. To inform patient caretaker to initiate the ART from GOVT.
Hospital .
 PHARMACIST INTERVENTION
Anti-TB and ART drugs at same time involves a number of
potential difficulties including - Cumulative drug toxicities Drug
– drug interactions, A high pill burden and The Immune
Reconstitution Inflammatory Syndrome (IRIS)
1. Concurrent use of pyrazinamide and riampin may result in severe
hepatic injury – major – delayed onset.
2. Concurrent use of rifmpin and isoniazid can cause
severe hepatic toxicuty, so monitor LFT.
MONITORING PARAMETER
CBC with ESR
LFT
CD4 COUNT
CLINICAL SYMPTOMS OF LIVER INJURY
TREATMENT
PHARMACOLOGICAL TREATMENT:
 ANTI-TB DRUGS:Agents that are therapeutically
effective against TB.
 First Line Drugs:They have high antitubercular
efficacy as well as low toxicity.
 Isoniazid(H)
 Rifampin(R)
 Pyrazinamide(Z)
 Ethambutol(E)
 Streptomycin(S)
 Second Line Drugs:They have either low Anti-TB
efficacy or high toxicity or both.
 Thiacetazone(Tzn)
 Para Amino Salicylic acid(PAS)
 Ethionamide(Etm)
 Cycloserine(Cys)
 NEWER DRUGS
 Ciprofloxacin
 Azithromycin
 Rifabutin
CATEGORY BASED TREATMENT
 Category I:New positive pulmonary TB patients.
 New severe extra pulmonary tuberculosis patients
 Negative for pulmonary TB with extensive paranchymal
involvement.
 Category II:Treatment failure due to resistance,inadequate
dose,uncompliance,relapse,multi-drug resistant TB
 Category III:Less severe extra TB
 Less negative for PTB with extensive parenchymal
involvement.
 Category IV:Chronic disease
 Multi-drug resistant TB
DOTS(Directly Observed Treatment
In Short Strategy)
 H3R3Z3E3/S3 for 2 months +H3R3 for 4 months
 Total therapy:6 months
 DOTS Therapy is directed to following people:
 Homeless people
 History of non-medication adherence patients.
 Chronic alcoholic
 Active TB
 TB with AIDS:2HRZE,Duration:9 months
 Mycobacterium avium complex in AIDS due to immune
suppression.Clarithromycin/Azithromycin+Etm+/-
Rifampin
According to revised national TB control program [RNTCP]
Category of Treatment Type of Patient Regimen
Category I New sputum smear-positive
Seriously ill** new sputum
smear-negative Seriously
ill** new extra-pulmonary
2H3R3Z3E3+ 4H3R3
Category II Sputum smear-positive
Relapse Sputum smear-
positive Failure Sputum
smear-positive Treatment
After Default Others
2H3R3Z3E3S3 + 1H3R3Z3E3 +
5H3R3E3
Category III New Sputum smear-
negative, not seriously ill
New Extra-pulmonary, not
seriously ill
2H3R3Z3 + 4H3R3
STANDARD TREATMENT -First line
drugs
The recommended preferred first-line ARV regimens
For infants and children are:
 Regimen of 2 NRTI plus 1 NNRTI
 AZT* + 3TC + NVP or EFV**
 D4T + 3TC + NVP or EFV**
 ABC+ 3TC + NVP or EFV is an alternative however, in the
national programme – ABC is not available and is still costly.
HIV with TB
 Anti TB should be started first & ART should be started 2-
8 weeks after anti TB for those individuals who have a CD4
count of less than 200mm.
 Increased risk of inflammatory immune reconstitution
syndrome
 Rifampicin lowers NVP drug level by 20-58% and EFV
drug level by 25%. In children, there is no information on
appropriate dosing of NVP and EFV when used with
Rifampicin.
 2NRTI + NVP
PATIENT COUNSELLING
 About disease : TB is a chronic granulomatous disease
caused by mycobacterium tuberculosis.
 RVD : A disease in which there is severe loss of body
cellular immunity , grately lowering the resistance to
infection and malignancy .
 About drug : Pantaprazole – taken half an hour before
meals
Benadon : taken with meals .
Cefotaxim : should Be taken after meals
INH+PYR+RIFAMPICIN – taken on empty stomach one
hour before meals.
LIFE STYLE MODIFICATION FOR RVD
WITH PTB
 Medication Adherence
 Potential adverse effects from and interactions with
antiretroviral drug therapy and ways to manage
adverse effects
 Educating the patient about modes of HIV
transmission and effective techniques for prevention
of transmission
 Nutritional assessment
 Psychological support
 Exercise
 Dont spit in the public places
 Avoid irritants (smoke , dust )
 Use mask while coughing
 About the administration of the drugs which the
doctor has prescribed
 Advice patients to report the signs of hepatic
dysfunction such as dark urine , decreased appetite ,
jaundice .
HIV AND PTB

More Related Content

What's hot

Case on type II diabetes mellitus with peripheral neuropathy with hypertension
Case on type II diabetes mellitus with peripheral neuropathy with hypertensionCase on type II diabetes mellitus with peripheral neuropathy with hypertension
Case on type II diabetes mellitus with peripheral neuropathy with hypertensionVineetha Menon
 
A case study on tuberculosis
A case study on tuberculosisA case study on tuberculosis
A case study on tuberculosis
DrMaheshGurajapu
 
TB MENINGITIS CASE PRESENTATION
 TB MENINGITIS CASE PRESENTATION  TB MENINGITIS CASE PRESENTATION
TB MENINGITIS CASE PRESENTATION
fareedresidency
 
Renal failure case presentation
Renal failure case presentationRenal failure case presentation
Renal failure case presentation
Rajnandini Singha
 
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
Rajnandini Singha
 
Case Presentation: Hypertension (A case on refusal of Evidence Based Medicine)
Case Presentation: Hypertension (A case on refusal of Evidence Based Medicine)Case Presentation: Hypertension (A case on refusal of Evidence Based Medicine)
Case Presentation: Hypertension (A case on refusal of Evidence Based Medicine)
Dr. Aryan (Anish Dhakal)
 
A CASE PRESENTATION ON COPD,CORPULMONALE
A CASE PRESENTATION ON COPD,CORPULMONALEA CASE PRESENTATION ON COPD,CORPULMONALE
A CASE PRESENTATION ON COPD,CORPULMONALE
Dr.Hashim Syed Ali (Dr.Foster)
 
4. a case study on pneumonia
4. a case study on pneumonia4. a case study on pneumonia
4. a case study on pneumonia
Dr. Ajita Sadhukhan
 
Seizures with right hemiparesis
Seizures with right hemiparesisSeizures with right hemiparesis
Seizures with right hemiparesis
Makbul Hussain Chowdhury
 
Acute gastroenteritis case study
Acute gastroenteritis case studyAcute gastroenteritis case study
Acute gastroenteritis case study
Maharshi Mallela
 
A Case Presentation on Tuberculous meningitis
A Case Presentation on Tuberculous meningitisA Case Presentation on Tuberculous meningitis
A Case Presentation on Tuberculous meningitis
DR. METI.BHARATH KUMAR
 
RNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended versionRNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended version
RxVichuZ
 
CASE PRESENTATION ON ACUTE INFECTIOUS HEPATITIS
CASE PRESENTATION ON ACUTE INFECTIOUS HEPATITISCASE PRESENTATION ON ACUTE INFECTIOUS HEPATITIS
CASE PRESENTATION ON ACUTE INFECTIOUS HEPATITIS
DR. METI.BHARATH KUMAR
 
Case presentation on cholera by varam
Case presentation on cholera by varamCase presentation on cholera by varam
Case presentation on cholera by varamsurya720
 
Hypothyroidism
HypothyroidismHypothyroidism
Hypothyroidism
Dr B Naga Raju
 
Management of TB 2019
Management of TB 2019Management of TB 2019
Management of TB 2019
Lifecare Centre
 
case presentation on HYPERTENSION
case presentation on HYPERTENSIONcase presentation on HYPERTENSION
case presentation on HYPERTENSION
JoshuaGeorge46
 
Interesting case of encephalitis
Interesting case of encephalitisInteresting case of encephalitis
Interesting case of encephalitis
Vasif Mayan
 
Case based presentation(Chronic renal failure and Dialysis)
Case based presentation(Chronic renal failure and Dialysis)Case based presentation(Chronic renal failure and Dialysis)
Case based presentation(Chronic renal failure and Dialysis)
Irum Khan
 
Case presentation on parkinson's disease
Case presentation on parkinson's diseaseCase presentation on parkinson's disease
Case presentation on parkinson's disease
Senthilraj93
 

What's hot (20)

Case on type II diabetes mellitus with peripheral neuropathy with hypertension
Case on type II diabetes mellitus with peripheral neuropathy with hypertensionCase on type II diabetes mellitus with peripheral neuropathy with hypertension
Case on type II diabetes mellitus with peripheral neuropathy with hypertension
 
A case study on tuberculosis
A case study on tuberculosisA case study on tuberculosis
A case study on tuberculosis
 
TB MENINGITIS CASE PRESENTATION
 TB MENINGITIS CASE PRESENTATION  TB MENINGITIS CASE PRESENTATION
TB MENINGITIS CASE PRESENTATION
 
Renal failure case presentation
Renal failure case presentationRenal failure case presentation
Renal failure case presentation
 
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
A CASE PRESENTATION ON GERD ( GASTROESOPHAGEAL REFLUX DISEASE)
 
Case Presentation: Hypertension (A case on refusal of Evidence Based Medicine)
Case Presentation: Hypertension (A case on refusal of Evidence Based Medicine)Case Presentation: Hypertension (A case on refusal of Evidence Based Medicine)
Case Presentation: Hypertension (A case on refusal of Evidence Based Medicine)
 
A CASE PRESENTATION ON COPD,CORPULMONALE
A CASE PRESENTATION ON COPD,CORPULMONALEA CASE PRESENTATION ON COPD,CORPULMONALE
A CASE PRESENTATION ON COPD,CORPULMONALE
 
4. a case study on pneumonia
4. a case study on pneumonia4. a case study on pneumonia
4. a case study on pneumonia
 
Seizures with right hemiparesis
Seizures with right hemiparesisSeizures with right hemiparesis
Seizures with right hemiparesis
 
Acute gastroenteritis case study
Acute gastroenteritis case studyAcute gastroenteritis case study
Acute gastroenteritis case study
 
A Case Presentation on Tuberculous meningitis
A Case Presentation on Tuberculous meningitisA Case Presentation on Tuberculous meningitis
A Case Presentation on Tuberculous meningitis
 
RNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended versionRNTCP guidelines for tuberculosis management: Extended version
RNTCP guidelines for tuberculosis management: Extended version
 
CASE PRESENTATION ON ACUTE INFECTIOUS HEPATITIS
CASE PRESENTATION ON ACUTE INFECTIOUS HEPATITISCASE PRESENTATION ON ACUTE INFECTIOUS HEPATITIS
CASE PRESENTATION ON ACUTE INFECTIOUS HEPATITIS
 
Case presentation on cholera by varam
Case presentation on cholera by varamCase presentation on cholera by varam
Case presentation on cholera by varam
 
Hypothyroidism
HypothyroidismHypothyroidism
Hypothyroidism
 
Management of TB 2019
Management of TB 2019Management of TB 2019
Management of TB 2019
 
case presentation on HYPERTENSION
case presentation on HYPERTENSIONcase presentation on HYPERTENSION
case presentation on HYPERTENSION
 
Interesting case of encephalitis
Interesting case of encephalitisInteresting case of encephalitis
Interesting case of encephalitis
 
Case based presentation(Chronic renal failure and Dialysis)
Case based presentation(Chronic renal failure and Dialysis)Case based presentation(Chronic renal failure and Dialysis)
Case based presentation(Chronic renal failure and Dialysis)
 
Case presentation on parkinson's disease
Case presentation on parkinson's diseaseCase presentation on parkinson's disease
Case presentation on parkinson's disease
 

Similar to HIV AND PTB

Tuberculosis
Tuberculosis Tuberculosis
Tuberculosis
Krunal Goyani
 
Pemphigus vulgaris
Pemphigus vulgarisPemphigus vulgaris
Pemphigus vulgaris
Zahed Ulla Khan
 
3. a case study on plasmodium falciparum with thrombocytopenia with viral hep...
3. a case study on plasmodium falciparum with thrombocytopenia with viral hep...3. a case study on plasmodium falciparum with thrombocytopenia with viral hep...
3. a case study on plasmodium falciparum with thrombocytopenia with viral hep...
Dr. Ajita Sadhukhan
 
Toxic epidermal necrolysis - drug induced (case presentation)
Toxic epidermal necrolysis - drug induced  (case presentation)Toxic epidermal necrolysis - drug induced  (case presentation)
Toxic epidermal necrolysis - drug induced (case presentation)
Srisharikakumar
 
Schistosomiasis
SchistosomiasisSchistosomiasis
Schistosomiasis
liza mariposque
 
HIV and TB coinfection
HIV and TB coinfectionHIV and TB coinfection
HIV and TB coinfection
swati2084
 
HIV - Human Immunodeficiency Virus
HIV - Human Immunodeficiency VirusHIV - Human Immunodeficiency Virus
HIV - Human Immunodeficiency Virus
Meenatchisundaram Subramani
 
Bovine tuberculosis: Occupational hazard in Abattoir workers
Bovine tuberculosis: Occupational hazard in Abattoir workersBovine tuberculosis: Occupational hazard in Abattoir workers
Bovine tuberculosis: Occupational hazard in Abattoir workers
iosrjce
 
168403278 case-fix
168403278 case-fix168403278 case-fix
168403278 case-fix
homeworkping8
 
differences in different diseases
differences in different diseasesdifferences in different diseases
differences in different diseases
Dr Ifsha Akhlaq
 
Laboratory diagnosis of Tuberculosis gs
Laboratory diagnosis of Tuberculosis gs Laboratory diagnosis of Tuberculosis gs
Laboratory diagnosis of Tuberculosis gs
Gaurav S
 
Diagnosis of Tuberculosis
Diagnosis of TuberculosisDiagnosis of Tuberculosis
Diagnosis of Tuberculosis
Dr. Amita Yadav
 
Tuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugsTuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugs
Narasimha Kumar G V
 
Tuberculosis diagnostics
Tuberculosis diagnosticsTuberculosis diagnostics
Tuberculosis diagnostics
Santi Silairatana
 
Staphylococci 09 10 Med
Staphylococci 09 10  MedStaphylococci 09 10  Med
Staphylococci 09 10 Medguestb0a8ba3
 
Case Study on Reteropositive with RF,LRTI,UTI and Sepsis .pptx
Case Study on Reteropositive with RF,LRTI,UTI and Sepsis .pptxCase Study on Reteropositive with RF,LRTI,UTI and Sepsis .pptx
Case Study on Reteropositive with RF,LRTI,UTI and Sepsis .pptx
Kamaljeet ..
 
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
write31
 
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
write22
 
Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumoniaBeena Philip
 
Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumoniaBeena Philip
 

Similar to HIV AND PTB (20)

Tuberculosis
Tuberculosis Tuberculosis
Tuberculosis
 
Pemphigus vulgaris
Pemphigus vulgarisPemphigus vulgaris
Pemphigus vulgaris
 
3. a case study on plasmodium falciparum with thrombocytopenia with viral hep...
3. a case study on plasmodium falciparum with thrombocytopenia with viral hep...3. a case study on plasmodium falciparum with thrombocytopenia with viral hep...
3. a case study on plasmodium falciparum with thrombocytopenia with viral hep...
 
Toxic epidermal necrolysis - drug induced (case presentation)
Toxic epidermal necrolysis - drug induced  (case presentation)Toxic epidermal necrolysis - drug induced  (case presentation)
Toxic epidermal necrolysis - drug induced (case presentation)
 
Schistosomiasis
SchistosomiasisSchistosomiasis
Schistosomiasis
 
HIV and TB coinfection
HIV and TB coinfectionHIV and TB coinfection
HIV and TB coinfection
 
HIV - Human Immunodeficiency Virus
HIV - Human Immunodeficiency VirusHIV - Human Immunodeficiency Virus
HIV - Human Immunodeficiency Virus
 
Bovine tuberculosis: Occupational hazard in Abattoir workers
Bovine tuberculosis: Occupational hazard in Abattoir workersBovine tuberculosis: Occupational hazard in Abattoir workers
Bovine tuberculosis: Occupational hazard in Abattoir workers
 
168403278 case-fix
168403278 case-fix168403278 case-fix
168403278 case-fix
 
differences in different diseases
differences in different diseasesdifferences in different diseases
differences in different diseases
 
Laboratory diagnosis of Tuberculosis gs
Laboratory diagnosis of Tuberculosis gs Laboratory diagnosis of Tuberculosis gs
Laboratory diagnosis of Tuberculosis gs
 
Diagnosis of Tuberculosis
Diagnosis of TuberculosisDiagnosis of Tuberculosis
Diagnosis of Tuberculosis
 
Tuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugsTuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugs
 
Tuberculosis diagnostics
Tuberculosis diagnosticsTuberculosis diagnostics
Tuberculosis diagnostics
 
Staphylococci 09 10 Med
Staphylococci 09 10  MedStaphylococci 09 10  Med
Staphylococci 09 10 Med
 
Case Study on Reteropositive with RF,LRTI,UTI and Sepsis .pptx
Case Study on Reteropositive with RF,LRTI,UTI and Sepsis .pptxCase Study on Reteropositive with RF,LRTI,UTI and Sepsis .pptx
Case Study on Reteropositive with RF,LRTI,UTI and Sepsis .pptx
 
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
 
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
Capstone assignment on Clostridium Perfringens Associates degree in Medical T...
 
Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumonia
 
Ventilator associated pneumonia
Ventilator associated pneumoniaVentilator associated pneumonia
Ventilator associated pneumonia
 

More from Akhil Joseph

Classification of Diseases
Classification of DiseasesClassification of Diseases
Classification of Diseases
Akhil Joseph
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
Akhil Joseph
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failure
Akhil Joseph
 
Classical versus atypical antipsychotics
Classical  versus  atypical antipsychoticsClassical  versus  atypical antipsychotics
Classical versus atypical antipsychotics
Akhil Joseph
 
Drug development process.
Drug development process.Drug development process.
Drug development process.
Akhil Joseph
 
Necrotizing fascitis
Necrotizing fascitisNecrotizing fascitis
Necrotizing fascitis
Akhil Joseph
 
CASE PRESENTATION ON CIRRHOSIS OF LIVER WITH PORTAL HYPERTENSION, HEPATIC EN...
CASE PRESENTATION ONCIRRHOSIS OF LIVER WITH PORTAL  HYPERTENSION, HEPATIC EN...CASE PRESENTATION ONCIRRHOSIS OF LIVER WITH PORTAL  HYPERTENSION, HEPATIC EN...
CASE PRESENTATION ON CIRRHOSIS OF LIVER WITH PORTAL HYPERTENSION, HEPATIC EN...
Akhil Joseph
 
Mental and behavioural disturbances due to use of alcohol with simple withdrwal
Mental and behavioural disturbances due to use of alcohol with simple withdrwalMental and behavioural disturbances due to use of alcohol with simple withdrwal
Mental and behavioural disturbances due to use of alcohol with simple withdrwal
Akhil Joseph
 
Microbiological culture sensitivity test
Microbiological culture sensitivity testMicrobiological culture sensitivity test
Microbiological culture sensitivity test
Akhil Joseph
 
Alzheimer’s disease
Alzheimer’s diseaseAlzheimer’s disease
Alzheimer’s disease
Akhil Joseph
 

More from Akhil Joseph (10)

Classification of Diseases
Classification of DiseasesClassification of Diseases
Classification of Diseases
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failure
 
Classical versus atypical antipsychotics
Classical  versus  atypical antipsychoticsClassical  versus  atypical antipsychotics
Classical versus atypical antipsychotics
 
Drug development process.
Drug development process.Drug development process.
Drug development process.
 
Necrotizing fascitis
Necrotizing fascitisNecrotizing fascitis
Necrotizing fascitis
 
CASE PRESENTATION ON CIRRHOSIS OF LIVER WITH PORTAL HYPERTENSION, HEPATIC EN...
CASE PRESENTATION ONCIRRHOSIS OF LIVER WITH PORTAL  HYPERTENSION, HEPATIC EN...CASE PRESENTATION ONCIRRHOSIS OF LIVER WITH PORTAL  HYPERTENSION, HEPATIC EN...
CASE PRESENTATION ON CIRRHOSIS OF LIVER WITH PORTAL HYPERTENSION, HEPATIC EN...
 
Mental and behavioural disturbances due to use of alcohol with simple withdrwal
Mental and behavioural disturbances due to use of alcohol with simple withdrwalMental and behavioural disturbances due to use of alcohol with simple withdrwal
Mental and behavioural disturbances due to use of alcohol with simple withdrwal
 
Microbiological culture sensitivity test
Microbiological culture sensitivity testMicrobiological culture sensitivity test
Microbiological culture sensitivity test
 
Alzheimer’s disease
Alzheimer’s diseaseAlzheimer’s disease
Alzheimer’s disease
 

Recently uploaded

Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
ESC Beyond Borders _From EU to You_ InfoPack general.pdf
ESC Beyond Borders _From EU to You_ InfoPack general.pdfESC Beyond Borders _From EU to You_ InfoPack general.pdf
ESC Beyond Borders _From EU to You_ InfoPack general.pdf
Fundacja Rozwoju Społeczeństwa Przedsiębiorczego
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
Fish and Chips - have they had their chips
Fish and Chips - have they had their chipsFish and Chips - have they had their chips
Fish and Chips - have they had their chips
GeoBlogs
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
Introduction to Quality Improvement Essentials
Introduction to Quality Improvement EssentialsIntroduction to Quality Improvement Essentials
Introduction to Quality Improvement Essentials
Excellence Foundation for South Sudan
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)
rosedainty
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
AzmatAli747758
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
Vivekanand Anglo Vedic Academy
 

Recently uploaded (20)

Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
ESC Beyond Borders _From EU to You_ InfoPack general.pdf
ESC Beyond Borders _From EU to You_ InfoPack general.pdfESC Beyond Borders _From EU to You_ InfoPack general.pdf
ESC Beyond Borders _From EU to You_ InfoPack general.pdf
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
Fish and Chips - have they had their chips
Fish and Chips - have they had their chipsFish and Chips - have they had their chips
Fish and Chips - have they had their chips
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
Introduction to Quality Improvement Essentials
Introduction to Quality Improvement EssentialsIntroduction to Quality Improvement Essentials
Introduction to Quality Improvement Essentials
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)Template Jadual Bertugas Kelas (Boleh Edit)
Template Jadual Bertugas Kelas (Boleh Edit)
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...Cambridge International AS  A Level Biology Coursebook - EBook (MaryFosbery J...
Cambridge International AS A Level Biology Coursebook - EBook (MaryFosbery J...
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......Ethnobotany and Ethnopharmacology ......
Ethnobotany and Ethnopharmacology ......
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
Sectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdfSectors of the Indian Economy - Class 10 Study Notes pdf
Sectors of the Indian Economy - Class 10 Study Notes pdf
 

HIV AND PTB

  • 2. DEFINITION  Tuberculosis is a chronic granulomatous disease caused by Mycobacterium tuberculosis,which can produce either a silent ,latent infection or a progressive,active disease.
  • 3. ETIOLOGY  Causative Organism:TB is caused by Mycobacterium species.  In humans,infection by M.tuberculosis.  In animals,infection by M.bovis.  In Africans,infection by M.africanum  M.tuberculosis is an aerobic,non-spore forming bacillus that resist decolourization by acid alcohol after staining with basic fuschin....organism is referred to as an acid fast bacilli(AFB).
  • 4. PATHOPHYSIOLOGY  Airborne/droplet ingestion (cough, sneezing,speaking) Droplet nuclei enter the respiratory tract and reach alveoli(bacteria enter ciliary epithelium) Initiation of primary infection(organisms multiply) Activation of alveolar macrophages(phagocytosis of bacilli)
  • 5. Persistence of organism(few in number) Rupture of macrophages & release of bacilli Organisms multiply, transport of bacilli by lymphatic system to other organs Formation of gra nuloma(cell mediated immunity delayed type of hypersensitivity by activation of CD4+T cells,secretion of INF gamma, IL ) Large number of macrophages surrounds the organism
  • 6. In high immune people disease may relapse after 2 yrs(latent tb infection) In immune suppressed people tubercular bacilli appear(rapid multiplication) Active tb infection
  • 7. CLINICAL PRESENTATION SIGNS AND SYMPTOMS:  Weight loss,fatigue,a productive cough,fever,and night sweats.  Frank hemoptysis PHYSICAL EXAMINATION:  Dullness to chest percussion,rales and increased vocal fremitus are observed frequently on auscultation. LAB TESTS:  Moderate elevations in WBC Count with a lymphocyte predominance.  Chest Radiograph:Patchy or nodular infiltrates in the apical areas of the upper lobes or the superior segment of the lower lobes  Cavitation that may show air fluid levels as the infection progresses.
  • 8. Definition AIDS, the acquired immune deficiency syndrome(some times called as slim disease) is a fatal illness caused by a retrovirus known as the human immunodeficiency virus(HIV) which breaks the body’s immune system, leaving the victim vulnerable to a host of life-threatening opportunistic infections, neurological disorders, or unusual malignancies.
  • 9. ETIOLOGY  AIDS is caused by HIV, a human retrovirus.  Two types- HIV I and HIV II which are genetically different but has related forms.  HIV I is most common type associated with AIDS in US, Europe and Central Africa.  HIV II causes similar disease in West Africa and India.  HIV-2 is transmitted less efficiently than HIV-1.
  • 10. 0
  • 12. COMMON SIGN & SYMPTOMS  Severe impairment or suppression of immune system.  Pneumocystis carinii pneumonia (pcp) is mostly seen.  Opportunistic infection  CD4+T- cells count falls below 200 cells/mm3 of blood.  In healthy adult it’s value is 600-1500 cells/mm3 of blood. • Weight loss • Pharyngitis • Neurological symptoms. • Rash • Headache  Fever  Lymphadenopathy
  • 13. DEMOGRAPHIC DETAILS  PATIENT NAME:ABC  SEX:M  DEPT:MEDICINE  DOA:10-12-2016  AGE:30yrs  IP NO:27687  UNIT:C  DOD:17-12-2016
  • 14. REASON FOR ADMISSION  C/O fever with chills since 1 week.  C/O cough since 1 week.  generalisedweakness +
  • 15. PAST MEDICAL HISTORY  Not a k/c/o HTN,DM,TB,epilepsy,anaemia
  • 16. HISTORY OF PRESENT ILLNESS  Patient was apparently alright but 7 days back he developed fever with chills,insidious in onset,intermittent type.  No H/O rigors  H/O dry cough since 7 days.  H/O breathlessness since 7 days.  H/O generalised weakness +
  • 17. FAMILY HISTORY  DIET:mixed  APPETITE:decreased  SLEEP:normal  B/B:regular
  • 18. SOCIAL HISTORY  Chronic Alcoholic  Tobacco Chewing
  • 19. GENERAL PHYSICAL EXAMINATION  Patient is moderately built and nourished,conscious,cooperative,well oriented to time,place and person.  O/E,  PR:90 bpm  BP:110/70mmHg  Febrile 1. PICKLE B/L Pitting pedal edema
  • 20. SYSTEMIC EXAMINATION  CVS:S1 S2 +  RS:NVBS+  CNS:NAD  P/A:soft,non-tender,no organomegaly
  • 21. INVESTIGATIONS  CBC with ESR  RBS  Serum Creatinine  LFT  Chest X-Ray  RVD  HBsAg  ECG  Urine Routine  Culture sensitivity test  USG Abdomen  MP Antigen
  • 22. PROVISIONAL DIAGNOSIS CHRONIC ALCOHOLIC CIRRHOSIS OF LIVER , SEVERE ANAEMIA ?
  • 23. LABORATORY DATA 11/12 13/12 Hb 3.3gm/dl(13.5-17.5) 6.0gm/dl WBC 1500cells/µl(4500-10500) 1800cells/µl POLYMORPHS 65%(40 -75) 53% BASOPHILS 00(0-1) 00 EOSINOPHILS 3%(0-5) 2% LYMPHOCYTES 32%(20-40) 45% MONOCYTES 00%(0-7) 0% RBC O.75mill/µ l(4.7-6.1) 1.53mill/µl PLATELETS 60,000cells/µl(1.5-4.5 lakhs) 110000cells/µl ESR 100mm at the end of the 1st hour
  • 24. 11/12 RBS 112 mg/dl(60-140) Sr . Urea 18 mg%(10-50) Sr . Creatinine 0.9 mg/dl(0.6-1.2) ALT 22 U/L(6-38) AST 68 U/L(6-40) ALP 122 U/L(35-140) T . Bilirubin 0.8 MG%(0.2-1) D . Bilirubin 0.3 MG %(0.1-0.4) I . Bilirubin 0.5 MG %(0.1-0.6) HIV - 1 Reactive HBs Ag - ve Albumin 3.1 gm %(3.5-5.2)
  • 25.  SPUTUM CULTURE SENSITIVITY TEST : organisms isolated .  ZN stain : AFB seen  USG abdomen : moderate to gross ascitis.  Pus cells : 1-2/hpf  Epithelial cells : 0-1/hpf
  • 26. TREATMENT CHART BRAND NAME GENERIC NAME DOSE ROUTE FREQUENCY 1 2 3 4 5 6 7 8 Blood Transfusion PRBC PACKAGED CELL VOLUME 3 PINT IV √ √ INJ.Taxim Cefotaxime 1gm iv 1-0-1 √ √ √ √ √ √ INJ.Pantakind Pantoprazole 40mg iv 1-0-0 √ √ √ √ √ √( t) √ √ INJ.Vitcofol 2 ml in 100ml NS folic acid,vitaminB12,nic otinamide 15mg, 0.15mg,200m g im 1-0-0 √ √ √ √ √ √ √ √ IVF DNS 2 pint iv 1-1-1 √ √ √ TAB.Sepmax DS Sulphamethoxazole ,trimethoprim 800mg,160m g p/o 1-0-0 √ √ √ √ √ √ TAB.Benadon Vit B6 40mg p/o 0-1/2-0 √ √ √ √ √ √ TAB.Akurit 4 INH,rif,pyr,ethamb utol 75mg,150mg, 400mg,275m g p/o 3-0-0 √ √ √ √ √ √
  • 27. FOLLOW UP  DAY 1  O/E,  BP:100/70 mmHg  PR:90 bpm  Febrile  S/E,  CVS:S1 S2 +  RS:NVBS+  CNS:NAD  P/A:Soft,non-tender
  • 28.  Adv:  Blood transfusion 3 pint whole blood  Inj.Taxim 1gm iv 1-0-1  Inj.Pantakind 40 mg iv 1-0-1  Inj.Vitcofol 2amp in 100 ml NS iv 1-0-0  IVF DNS 2 pint with mvi
  • 29.  DAY 2  O/E,  BP:110/70mmHg  PR:80 bpm  S/E,  CVS:S1 S2 +  RS:NVBS+  CNS:NAD  P/A:Soft non-tender
  • 30.  Adv:  Inj.Taxim 1gm iv 1-0-1  Inj.Pantakind 40mg iv 1-0-0  Inj.Vitcofol 2 amp in 100 ml NS iv 1-0 -0  IVF DNS 2 pint with mvi  Tab.Sepmax DS 1-0-0  Tab.Akurit 4 3-0-0  Tab.Benadon 40mg 0-1/2-0
  • 31.  DAY 3  O/E,  BP:110/60mmHg  PR:80 bpm  S/E,  CVS:S1 S2 +  RS :NVBS +  CNS:NAD  P/A :soft non tender
  • 32.  Adv:  Inj. Taxim 1g iv 1-0-1  Inj. Pantakind 40mg iv 1-0-0  Inj. Vitcofol 2 amp. In 100 ml NS IV 1-0-0  Tab.Sepmax DS 1-0-0  Tab. Akurit 4 3-0-0  Tab. Benadon 40mg 0-1/2-0
  • 33.  DAY 4  O/E,  BP:120/60mmHg  PR:88bpm  Afebrile  S/E  CVS:S1,S2 +  RS:NVBS+  CNS:NAD  P/A:Soft non tender
  • 35.  DAY 5  O/E  BP:110/60mmHg  PR:88bpm  Afebrile,  S/E  CVS:S1,S2 +  RS:NVBS+  CNS:NAD  P/A:Soft non tender
  • 37.  DAY 6  O/E:  BP:110/60mmHg  PR:80bpm  Afebrile  S/E:  CVS:S1,S2 +  RS:NVBS+  CNS:NAD  P/A:Soft non tender
  • 38.  Adv:  Tab.pantakind 40 mg 1-0-0  Inj. Vitcofol 2cc in 100ml NS iv 1-0-0  Tab.Sepmax DS 1-0-0  Tab. Akurit 4 3-0-0  Tab.Benadon 40mg 0-1/2-0
  • 39.  DAY 7  O/E:  BP:110/70mmHg  PR:84bpm  S/E:  CVS:S1,S2 +  RS:NVBS+  CNS:NAD  P/A : Soft non tender
  • 41. FINAL DIAGNOSIS  FROM THE SUBJECTIVE AND OBJECTIVE EVIDENCES , THE PHYSICIAN DIAGNOSED IT AS “RVD POSITIVE ,PULMONARY TB , PANCYTOPENIA”
  • 42. DISCHARGE MEDICATION BRAND GENERIC NAME DOSE ROUTE FREQUENC Y DURATION T.AKURIT 4 INH,PYR,EHAMBUTOL,RIFAM PICIN 75mg,400mg,2 75mg,150mg P/O 3-0-0 90 DAYS T.BENADONE VIT B6 40 mg P/O 0-1/2-0 90 DAYS T.SEPMAX DS SULPHAMETHOXAZOLE,TRIM ETHOPRIM 800 mg,160 mg P/O 1-0-0 30DAYS T.PANTAKIND PANTAPRAZOLE 40 mg P/O 1-0-0 10DAYS SYP.VICTOFOL FOLIC ACID,VIT B12,NICOTINAMIDE 15mg,0.15mg,2 00mg p/o 1-0-0 10DAYS
  • 43. PHARMACEUTICAL CARE PLAN  SUBJECTIVE EVIDENCE : c/o fever with chills since 1 week , c/o cough since 1 week . Generalized weakness +ve  OBJECTIVE EVIDENCE : HB : 6gm/dl ↓ WBC : 1500cells/ul ↓ RBC : 1.53mill/ul ↓ PLATELETS : 110000 cells/ul ↓ ESR : 100 mm at the end of the first hour ↑ HIV 1 : REACTIVE CULTURE SENSITIVITY TEST : Organisms isolated ZN stain : AFB seen USG abdomen : moderate gross ascites ALBUMIN : 3.1 gm%
  • 44. ASSESSMENT : By observing the subjective and objective evidences , the physician diagnosed it as “ RVD +ve , PTB , PANCYTOPENIA “ PLANNING:  GOALS OF THE THERAPY : 1. To decrease the fever , chills and cough . 2. To improve patient’s quality of life . 3. To make patient adhere to the medication . 4. To incease Hb and RBC counts . 5. To prevent further oppurtunistic infections. 6. To recommend the best ART regimen.
  • 45.  GOALS ACHIEVED 1. Fever, chills and cough reduced 2. patients quality of life is improved 3. Haemoglobin and RBC count is increased. 4. To inform patient caretaker to initiate the ART from GOVT. Hospital .  PHARMACIST INTERVENTION Anti-TB and ART drugs at same time involves a number of potential difficulties including - Cumulative drug toxicities Drug – drug interactions, A high pill burden and The Immune Reconstitution Inflammatory Syndrome (IRIS) 1. Concurrent use of pyrazinamide and riampin may result in severe hepatic injury – major – delayed onset.
  • 46. 2. Concurrent use of rifmpin and isoniazid can cause severe hepatic toxicuty, so monitor LFT. MONITORING PARAMETER CBC with ESR LFT CD4 COUNT CLINICAL SYMPTOMS OF LIVER INJURY
  • 47. TREATMENT PHARMACOLOGICAL TREATMENT:  ANTI-TB DRUGS:Agents that are therapeutically effective against TB.  First Line Drugs:They have high antitubercular efficacy as well as low toxicity.  Isoniazid(H)  Rifampin(R)  Pyrazinamide(Z)  Ethambutol(E)  Streptomycin(S)
  • 48.  Second Line Drugs:They have either low Anti-TB efficacy or high toxicity or both.  Thiacetazone(Tzn)  Para Amino Salicylic acid(PAS)  Ethionamide(Etm)  Cycloserine(Cys)  NEWER DRUGS  Ciprofloxacin  Azithromycin  Rifabutin
  • 49. CATEGORY BASED TREATMENT  Category I:New positive pulmonary TB patients.  New severe extra pulmonary tuberculosis patients  Negative for pulmonary TB with extensive paranchymal involvement.  Category II:Treatment failure due to resistance,inadequate dose,uncompliance,relapse,multi-drug resistant TB  Category III:Less severe extra TB  Less negative for PTB with extensive parenchymal involvement.  Category IV:Chronic disease  Multi-drug resistant TB
  • 50. DOTS(Directly Observed Treatment In Short Strategy)  H3R3Z3E3/S3 for 2 months +H3R3 for 4 months  Total therapy:6 months  DOTS Therapy is directed to following people:  Homeless people  History of non-medication adherence patients.  Chronic alcoholic  Active TB  TB with AIDS:2HRZE,Duration:9 months  Mycobacterium avium complex in AIDS due to immune suppression.Clarithromycin/Azithromycin+Etm+/- Rifampin
  • 51. According to revised national TB control program [RNTCP] Category of Treatment Type of Patient Regimen Category I New sputum smear-positive Seriously ill** new sputum smear-negative Seriously ill** new extra-pulmonary 2H3R3Z3E3+ 4H3R3 Category II Sputum smear-positive Relapse Sputum smear- positive Failure Sputum smear-positive Treatment After Default Others 2H3R3Z3E3S3 + 1H3R3Z3E3 + 5H3R3E3 Category III New Sputum smear- negative, not seriously ill New Extra-pulmonary, not seriously ill 2H3R3Z3 + 4H3R3
  • 52. STANDARD TREATMENT -First line drugs The recommended preferred first-line ARV regimens For infants and children are:  Regimen of 2 NRTI plus 1 NNRTI  AZT* + 3TC + NVP or EFV**  D4T + 3TC + NVP or EFV**  ABC+ 3TC + NVP or EFV is an alternative however, in the national programme – ABC is not available and is still costly.
  • 53. HIV with TB  Anti TB should be started first & ART should be started 2- 8 weeks after anti TB for those individuals who have a CD4 count of less than 200mm.  Increased risk of inflammatory immune reconstitution syndrome  Rifampicin lowers NVP drug level by 20-58% and EFV drug level by 25%. In children, there is no information on appropriate dosing of NVP and EFV when used with Rifampicin.  2NRTI + NVP
  • 54. PATIENT COUNSELLING  About disease : TB is a chronic granulomatous disease caused by mycobacterium tuberculosis.  RVD : A disease in which there is severe loss of body cellular immunity , grately lowering the resistance to infection and malignancy .  About drug : Pantaprazole – taken half an hour before meals Benadon : taken with meals . Cefotaxim : should Be taken after meals INH+PYR+RIFAMPICIN – taken on empty stomach one hour before meals.
  • 55. LIFE STYLE MODIFICATION FOR RVD WITH PTB  Medication Adherence  Potential adverse effects from and interactions with antiretroviral drug therapy and ways to manage adverse effects  Educating the patient about modes of HIV transmission and effective techniques for prevention of transmission  Nutritional assessment  Psychological support  Exercise
  • 56.  Dont spit in the public places  Avoid irritants (smoke , dust )  Use mask while coughing  About the administration of the drugs which the doctor has prescribed  Advice patients to report the signs of hepatic dysfunction such as dark urine , decreased appetite , jaundice .